Fabrication and characterization of DNA-loaded zein nanospheres
© Regier et al.; licensee BioMed Central Ltd. 2012
Received: 7 June 2012
Accepted: 27 November 2012
Published: 2 December 2012
Particulates incorporating DNA are promising vehicles for gene delivery, with the ability to protect DNA and provide for controlled, localized, and sustained release and transfection. Zein, a hydrophobic protein from corn, is biocompatible and has properties that make it a promising candidate material for particulate delivery, including its ability to form nanospheres through coacervation and its insolubility under physiological conditions, making it capable of sustained release of encapsulated compounds. Due to the promise of this natural biomaterial for drug delivery, the objective of this study was to formulate zein nanospheres encapsulating DNA as the therapeutic compound, and to characterize size, charge, sustained release, cell cytotoxicity and cellular internalization of these particles.
Zein nanospheres encapsulating DNA were fabricated using a coacervation technique, without the use of harsh solvents or temperatures, resulting in the preservation of DNA integrity and particles with diameters that ranged from 157.8 ± 3.9 nm to 396.8 ± 16.1 nm, depending on zein to DNA ratio. DNA encapsulation efficiencies were maximized to 65.3 ± 1.9% with a maximum loading of 6.1 ± 0.2 mg DNA/g zein. The spheres protected encapsulated DNA from DNase I degradation and exhibited sustained plasmid release for at least 7 days, with minimal burst during the initial phase of release. Zein/DNA nanospheres demonstrated robust biocompatibility, cellular association, and internalization.
This study represents the first report on the formation of zein particles encapsulating plasmid DNA, using simple fabrication techniques resulting in preservation of plasmid integrity and tunable sizes. DNA encapsulation efficiencies were maximized to acceptable levels at higher zein to DNA ratios, while loading was comparable to that of other hydrophilic compounds encapsulated in zein and that of DNA incorporated into PLGA nano- and microspheres. The hydrophobic nature of zein resulted in spheres capable of sustained release of plasmid DNA. Zein particles may be an excellent potential tool for the delivery of DNA with the ability to be fine-tuned for specific applications including oral gene delivery, intramuscular delivery, and in the fabrication of tissue engineering scaffolds.
KeywordsGene delivery Nonviral Zein DNA Nanoparticle Oral delivery Intramuscular injection
Gene delivery, the introduction of exogenous DNA into cells with subsequent expression, is applicable to the fields of gene therapy , DNA vaccination , functional genomics and diagnostics , and tissue engineering . Because of the technical and safety issues associated with viral gene delivery, the use of plasmid DNA (pDNA), which has lower immunogenicity, more flexibility in transgene capacity, and has the potential for industrial production, is an appealing alternative for gene transfer . Delivery of pDNA can result in the expression of a therapeutic gene or induction of protective immunity [2, 6]. Although the injection of naked pDNA can lead to transgene expression, the level and localization of expression are limited by rapid degradation by nucleases in the serum and clearance by the mononuclear phagocyte system . Encapsulation of pDNA has the potential to improve in vivo response and transfection by shielding the CpG methylation patterns of pDNA from the immune system, shielding the plasmid from degradation by enzymes and low pH, increasing residence time, and providing a controlled release . Nano- and microspheres incorporating pDNA, which administer pDNA in a controlled, sustained, and localized/targeted manner through the use of polymer systems that entrap pDNA and release it through hydrolytic or enzymatic mechanisms, have been applied to gene therapy, DNA vaccination, and tissue engineering [7, 8].
For gene therapy and DNA vaccination applications, several routes of administration for DNA delivery systems are possible, including oral delivery and intramuscular injection. The oral route is perhaps the most appealing, due to its associated high patient compliance and convenience. The oral route has the additional advantages of presenting a large surface area of intestinal epithelium for transfection and allowing treatment of regional disorders by providing access to the luminal side of the intestine . Oral gene delivery has the potential to treat diseases associated with the gastro-intestinal tract (GI-tract)  as well as systemic diseases , and can provide for systemic and mucosal immunity . However, oral delivery of DNA is complicated by low pH in the stomach and DNases in the GI-tract , which degrade unprotected DNA. Particulates are considered a viable tool for the protection of DNA from the harsh environment of the stomach and intestine . Previous studies have focused on poly(lactide-co-glycolide) (PLGA) and chitosan to form DNA-loaded nano- and microspheres for oral gene delivery [7, 15–17]. While these delivery vehicles have been shown to elicit the production of a therapeutic or immune response inducing protein, the level of protein produced is often modest with high variability [16, 18]. Furthermore, although these materials have provided a valuable proof of concept, their lack of sufficient efficacy suggests that new polymers need to be investigated.
The oral route of administration is not the only route of interest for gene therapy and DNA vaccination. The direct injection of DNA delivery systems into muscle has been investigated for DNA vaccination  and gene therapy . Injection of DNA-loaded nanoparticles and microparticles into muscle primarily results in local transfection because the particles do not readily diffuse from the tissue. Transfection of muscle cells can elicit an immune response , can result in a physiological change in the injected muscle , or can serve as a depot releasing the encoded protein into circulation . Particulate DNA delivery vehicles have been shown to increase the magnitude and duration of transgene expression compared to other delivery vehicles or naked DNA administered intramuscularly [7, 22]. However, as for oral delivery of DNA-loaded particulates, lack of sufficient efficacy with intramuscular administration suggests that new polymers need to be investigated for DNA delivery.
Natural polymers have been applied to drug and gene delivery and tissue engineering applications, and have the advantages of providing innate degradability and bioactivity [23, 24], but typically suffer from low mechanical properties, poor water stability, limited ability to be processed, and a relatively short release period compared to synthetic polymers [8, 25]. However, some natural polymers derived from plants, including wheat gluten, glutenin, zein, soy protein, cellulose, and starch [26–28] overcome some of the shortcomings of natural polymers. Among the various plant proteins, zein, the prolamin or storage protein from corn, has properties that make it a promising candidate material for particulate delivery. Zein is composed of three fractions, which are defined by their molecular weight and solubility, including α (75-85% of total zein, 21–25 kDa and 10 kDa), β (10-15% of total zein , 17–18 kDa), and γ (5-10% of total zein, 27 kDa) zein . More than 50% of the 225 amino acid residues  of zein are hydrophobic , including high percentages of leucine, proline, and alanine, which renders it insoluble under physiological conditions and capable of sustained release of encapsulated compounds . Zein also has a high glutamine content [33, 34], contributing polar, protonable side chains. With its amphiphilic character , the hydrophobic regions of zein can cause aggregation into colloidal particles, and the polar side chains allow for interaction with DNA. The surface charge of zein varies with the pH of the environment , with an isoelectric point of α-zein at pH 6.8 . Degradation of zein occurs very slowly by hydrolysis but is accelerated by the action of enzymes  and has been shown to be especially well-suited for oral delivery [37–39]. Zein has been shown to be biocompatible and to have degradation products that can enhance cell proliferation . Furthermore, part of the N-terminal region of γ-zein has been shown to interact with cell membranes and has served as a peptide carrier for drugs across cell membranes .
Nano- and microspheres composed of zein can be fabricated using a simple coacervation technique, which involves no harsh solvents or high temperatures. Zein microparticles have successfully been used to orally deliver ivermectin in a canine model  and desmopressin in a Phase I clinical trial . However, to the best of our knowledge, there have been no reports on the fabrication of zein nanospheres encapsulating a large, charged and hydrophilic molecule, like pDNA. Due to the promise of this natural biomaterial for drug delivery, including its biocompatibility, promotion of cell proliferation, capability for sustained release, interaction with cell membranes, and its versatility to interact, encapsulate and protect cargo, the objective of this study was to formulate and characterize zein nanospheres encapsulating DNA as the therapeutic compound, and to perform investigations into their ability for sustained DNA release, as well as to characterize cell cytotoxicity and internalization.
Results & discussion
Coacervation, the separation of solutions into colloidal systems with two liquid phases , was used to form spheres. This separation involves the formation of one phase rich in polymer (the coacervate) and another phase lacking polymer, which is brought about by the partial desolvation of a previously dissolved polymer [42–44]. Decreasing the ethanol concentration of dissolved zein solutions by the addition of aqueous solutions results in the necessary desolvation and the formation of a zein-rich nanosphere phase . This method has been previously used to encapsulate a variety of drugs [46–49], however, to the best of our knowledge, no published studies have reported on the encapsulation of DNA in zein. In this current study, pDNA was included with the aqueous solution added to desolvate zein, which resulted in the encapsulation of pDNA within the zein nanosphere phase formed through coacervation. Encapsulation of hydrophilic pDNA within the hydrophobic zein spheres was enhanced by lowering the pH of the initial ethanolic zein solution, which resulted in a net positive charge on the protein due to its higher isoelectric point . This change in charge promoted the electrostatic interaction of the zein and the negatively charged pDNA. During formation, suspensions of DNA-loaded zein nanospheres were free of visible aggregates during formation while blank spheres resulted in some visible aggregates (data not shown). Prior to centrifugation and collection of the spheres, the pH of the zein nanosphere suspensions was raised to 10 to lower the surface charge of the spheres to ~ −70 mV (a value sufficiently far from zero), resulting in repulsive forces between spheres to prevent irreversible aggregation of the spheres after centrifugation, and allowing for resuspension of the pelleted spheres for further analysis and delivery to cells. This sphere formation, centrifugation, and resuspenison procedure allowed for the simple and repeatable production of pDNA-loaded nanospheres, which were then characterized.
Spheres were characterized in PBS to assess the stability of spheres in a solution with physiological salt concentration and pH. In this environment, size measurements above 10 μm (which is beyond the detection limit of the DLS instrument and thus should not be considered accurate) and PdI values over 0.5 for both 20:1 and 40:1 zein:DNA spheres align with the observation of aggregation at these ratios (Figure 2B, D). For 80:1 and higher zein:DNA ratios, spheres did not aggregate in PBS and measured sizes were much lower than those of 20:1 and 40:1 particles in PBS, but were still higher than those measured in water. These larger sizes, between 740 and 1120 nm, measured in PBS were attributed to salt induced aggregation , which was subsequently verified by measuring size and zeta potential and noting the degree of resuspension and aggregation in solutions with varying salt concentrations (Additional file 1: Figure S1). Spheres formulated at the higher zein:DNA ratios showed no or little change in size over three hours in both water and PBS. The zeta potentials of the spheres formed at the various zein to DNA ratios were relatively uniform in both water and PBS, with values distributed between −20 and −50 mV (Figure 2E, F). Negative values were expected as zein has an isoelectric point of 6.8  and DNA is also negatively charged at physiological pH.
Overall, the characteristics of the zein/DNA nanospheres formulated in this study suggest that the spheres could be well-suited for oral administration, particularly for DNA vaccination, as particles less than 10 μm in diameter are taken up transparacellularly by Peyer’s patches in the intestine , a target for DNA-encoding antigens because of their proximity to gut-associated lymphoid tissue . Stabilization of the 20:1 and 40:1 particles could lend them to oral administration for gene therapy where widespread transfection is desired or for intramuscular injection, since particles less than 200 nm in diameter are taken up by endocytosis . While the negative surface charge measured for the zein/DNA spheres may prevent favorable interactions with the negatively charged cell membrane, a negative surface charge may impart mucoadhesive properties to the particles, which could increase intestinal residence time , further enhancing the ability of these particles to be used for oral administration of DNA therapeutics. In addition, zein/DNA nanospheres could be used for intramuscular injection, for DNA vaccination , to deliver a therapeutic gene targeted to muscle tissue , or for systemic gene therapy . Although the efficacy of the zein/DNA nanospheres formulated as described in this study could benefit from stabilization under physiological conditions and alteration of the surface charge, the spheres have appropriate size and uniformity for delivery of genes.
Encapsulation & loading
In this work, zein, a natural protein, was investigated as a possible material for the formation of spheres encapsulating pDNA for gene delivery. Zein is a protein that is insoluble under physiological conditions, which can allow for sustained release of encapsulated compounds and enable zein to act more like a hydrophobic polymer (i.e. PLGA). Zein is biocompatible and has degradation products that can enhance cell proliferation . Furthermore, part of the N-terminal region of γ-zein has been shown to interact with cell membranes and has served as a peptide carrier for drugs across cell membranes . Zein is commonly used in pharmaceutical tableting and coating, and is considered most promising for applications in edible and biodegradable packaging and coatings as well as biomedical applications . Zein has also shown great potential in the field of drug delivery [40, 65, 66], but previous studies have focused on small molecule, hydrophobic drugs. However, properties of zein make it well-suited for the development of nonviral gene delivery systems. Here, zein nanospheres encapsulating DNA were formed using a simple coacervation method, without the use of harsh solvents or temperatures, resulting in the preservation of pDNA integrity and tunable sizes. DNA encapsulation efficiencies were maximized to acceptable levels at higher zein to DNA ratios, while loading was comparable to that of other hydrophilic compounds encapsulated in zein and that of DNA incorporated into PLGA nano- and microspheres. The spheres were able to protect encapsulated DNA against degradation by DNAse I, and the hydrophobic nature of zein resulted in spheres capable of sustained release of plasmid DNA. Zein-DNA nanospheres showed biocompatibility with cells, and microscopy of cells with nano/microspheres indicated that the particles were highly associated with cells and were internalized. Future work will include modifications to improve cellular uptake and transfection. Zein appears to be an excellent potential tool for the delivery of DNA with the ability to be fine-tuned for specific applications including oral gene delivery, intramuscular injection, and in the fabrication of tissue engineering scaffolds.
Materials and methods
All experiments used pDsRed2-N1 (Clontech, Mountain View, CA), a plasmid encoding for the red fluorescent protein, DsRed2. The plasmid was purified from bacteria culture using Qiagen (Valencia, CA) reagents and stored in Tris-EDTA (TE) buffer solution (10 mM Tris, 1 mM EDTA, pH 7.4) at −20°C. Only plasmids with purity of 1.8 or better measured by 260/280 ratio (Nanodrop 2000 Spectrophotometer, Thermo Scientific, Waltham, MA) were used.
Zein spheres were formed by the coacervation technique. Zein (Freeman Industries LLC, Tuckahoe, New York) was first dissolved in 70% ethanol at pH 3 (pH adjusted with 1 M hydrochloric acid) forming a 1% w/v zein solution. Subsequently, 1 mL of 100% ethanol pH 3 was added to 1 mL of the 1% zein solution. A total of 1 mL of DsRed2 plasmid DNA (1 mg/mL in TE buffer) and TE buffer were added, followed by the dropwise addition of 10 mL ddH2O (18.2 mΩ-cm) while vortexing. Spheres were formed by coacervation during the addition of the ddH2O. The zein to DNA ratio was determined by the amount of DNA solution added and ranged from 20:1 to 250:1. Blank spheres were formed without DNA (TE buffer substituted for DNA solution). The pH of the resultant sphere suspension was increased to 10 by the addition of 1 M NaOH so that the spheres could be resuspended, as this pH induced sufficient surface charge on the spheres to prevent aggregation during centrifugation [67–69]. Spheres were then pelleted by centrifugation at 10,000 g for 1 hour at room temperature. The supernatant was removed and spheres were resuspended in ddH2O.
Field-emission scanning electron microscopy
Scanning electron microscopy (SEM, S4700 Field-Emission SEM, Hitachi, Japan) was used to image and subsequently analyze sphere size and morphology. For SEM imaging, spheres were resuspended in 2 mL of ddH2O and lyophilized. The lyophilized powder was placed in a thin layer on carbon tape (Electron Microscopy Sciences, Hatfield, PA) and mounted for imaging. Spheres were then sputter coated with chromium and imaged at 10 kV and varying magnifications. Three micrographs for each ratio were analyzed using Image J (NIH, Bethesda, MD) to determine average sphere diameter.
Dynamic light scattering
A dynamic light scattering (DLS) analyzer (Zetasizer Nano ZS90, Malvern Instruments Ltd, UK) was used to measure the mean diameter and particle size distribution of spheres after dilution in either 1X Dulbecco’s phosphate buffered saline (PBS, Invitrogen, Carlsbad, CA) or ddH2O. For dilution in PBS, spheres were first resuspended in 2 mL of water and then diluted further with 1X PBS due to the inability of spheres to initially be completely resuspended in PBS. Intensity mean diameter was used to express average particle size. The same instrument was used to measure the zeta potential of the spheres by a combination of laser Doppler velocimetry and phase analysis light scattering. Sphere suspensions above were likewise diluted in 1X PBS or ddH2O before measurement. Size, zeta potential and the polydispersity index (PdI) were measured directly after resuspension and 3 hours after resuspension for each sample to assess stability. To determine the cause of aggregation of the spheres in PBS and the inability of pelleted spheres to be resuspended in PBS, sphere size and zeta potential were similarly measured at various salt concentrations. The spheres were resuspended and diluted in 1X PBS or ddH2O with NaCl concentrations of 300, 150, 50 and 10 mM. Size and zeta potential were measured before centrifugation and again after centrifugation and resuspension. The degree of resuspension was noted for all conditions.
Encapsulation & loading
Sphere extraction solutions and release samples (as described below) were analyzed for plasmid integrity, as was the ability of the spheres to protect encapsulated pDNA from endonucleases. For the latter, naked pDNA (10 μg) and DNA-loaded zein spheres (equivalent to 10 μg of pDNA) were treated with 7.5 U of DNase I (Promega, Madison, WI) and incubated for 15 min at 37°C. The reaction was stopped by adding 50 mM Ethylenediaminetetraacetic acid (EDTA) and incubating at 65°C for 10 min. The integrity of the pDNA was analyzed by agarose (1%) gel electrophoresis. DNA was detected using ethidium bromide (Fisher BioReagents). A Kodak gel documentation system (EDAS 290, Kodak, Rochester, NY) was used to capture digital images of the gels.
For release studies, pelleted spheres were resuspended in 2 mL ddH2O. Separate samples for each time point were prepared by diluting 150 μL of sphere suspension (containing approximately 750 μg of zein and 4.3 μg of DNA) in 3 mL of release media. These samples were incubated in a humidified 37°C chamber for varying times. At predetermined time points, an entire sample was removed from the incubator and spheres were separated from the supernatant by centrifugation. The spheres and the supernatant were extracted with phenol/chloroform and DNA was quantified by Hoechst assay, both as described above.
Human embryonic epithelial kidney cells, HEK 293T (ATCC, Manassas, VA), were cultured in T-75 flasks in Dulbecco’s modified Eagle’s medium (DMEM, Gibco/Invitrogen, Carlsbad, CA) containing 4.5 g/L glucose and supplemented with 10% fetal bovine serum (FBS, Gibco), 2 mM L-glutamine (Gibco), and 1% penicillin/streptomycin (Gibco). For seeding, cells were counted using a hemocytometer and trypan blue staining for viable cells after being dissociated with 1 mM EDTA. Human colon carcinoma cells, Caco-2, were obtained from ATCC and were cultured in T-75 flasks in Eagle’s minimum essential medium (EMEM, ATCC) supplemented with 20% FBS (Gibco) and 1% penicillin/streptomycin (Gibco). For seeding, cells were dissociated with 0.05% trypsin/EDTA (Gibco). For both cell lines, cells were seeded into 48-well plates or 8-well Nunc Lab-Tek chambered coverglass slides (Thermo Scientific) at a density of 30,000-33,000 cells per well for HEK 293T cells and 25,000 cells per well for Caco-2 cells.
Cytotoxicity was assessed using a Water Soluble Tetrazolium (WST-1) salts cell proliferation assay kit (Roche, Indianapolis, IN). For the WST-1 assay, nanospheres containing 0.1, 0.25, 0.5, 1.0 or 2.0 μg of DNA were formed at a zein to DNA ratio of 80:1, resuspended in 1 mL ddH2O, and then diluted in OptiMem (Gibco) to a final volume of 75 μL. Cells were seeded in 48-well plates as described above and after 24 hours of culture, zein/DNA nanospheres were added to the culture media in triplicate wells. Cells were imaged to observe cell morphology (Leica DMI 3000B, Bannockburn, IL) and the WST-1 assay was conducted according to the manufacturer’s protocol at 24, 48, and 72 hours after the addition of zein nanospheres. Briefly, cells were washed with PBS, and incubated at 37°C with the WST-1 solution (10 vol.% WST-1 reagent in phenol-free DMEM, 400 μl /well). After incubation for 3 hours, absorbance values of WST-1 solution (100 μl from each well) were measured on an Epoch Microplate spectrophotometer (BioTek, Winooski, VT) at a wavelength of 430 nm. Assays were performed in triplicate on duplicate days.
To verify that confocal microscopy could be used to image zein/DNA nanospheres without labeling, the autofluorescence of zein was investigated. The autofluorescence of various zein concentrations in 70% ethanol was measured in a fluorometer with ultraviolet and blue modules. Once autofluorescence was confirmed, confocal microscopy was used to assess cellular morphology in response to the zein nanospheres, as well as to analyze cellular association of the spheres. Caco-2 and HEK 293T cells cultured with 80:1 or 250:1 nanospheres were imaged using a confocal microscope (Olympus IX 81, Olympus, Center Valley, PA). Cells were seeded as described above into 8-well coverslides. Zein spheres were visualized with an excitation wavelength of (405 nm) and an emission wavelength of (590 nm) and these images were overlaid with corresponding phase images.
To assess internalization of zein nanospheres, Caco-2 cells were seeded onto 8-well coverslides described above and after 36 hours of culture, media was replaced and zein/DNA nanospheres containing 0.1 μg DNA at a zein to DNA ratio of 80:1 were added to the fresh culture media. Twelve hours after the media change and addition of spheres, the cells were washed and then stained using Vybrant DiO cell-labeling solution (Molecular Probes/Life Technologies, Carlsbad, CA) for 25 minutes at 37° C according to the manufacturer’s protocol. Cells were then washed with PBS and fixed with 10% buffered formalin for 10 minutes. Following staining, confocal microscopy was performed, with zein and DiO sequentially excited using dual excitation of 405 and 543 nm for zein and 488 nm for DiO. A series of 15 optical sections in the Z-plane were acquired at intervals of 1 μm for at least two different locations per well and images were processed using Olympus FluoView software (v.5.0) to determine location of the spheres relative to cellular membranes.
All experiments were performed between three and six times (noted in figure legends). Comparative analyses were completed using a student’s t-test or one-way ANOVA followed by Tukey’s multiple comparison test for multiple data points, both at a 95% confidence level using Prism software (GraphPad Prism 5, LaJolla, CA). Mean values with standard error of the mean are reported for all data.
Support for this research was provided in part by funds from the American Heart Association, the University of Nebraska Foundation (Layman Funds), the Nebraska Research Initiative, USDA CSREES-Nebraska (NEB-21-146), and the Institute of Agriculture and Natural Resources Seed Grant Program. Confocal and scanning electron microscopy were performed at the University of Nebraska-Lincoln’s Center for Biotechnology Morrison Microscopy Core Research Facility and we thank Dr. You Zhou and Dr. Han Chen for assistance with imaging. We thank Dr. Shannon Bartelt-Hunt for the use of the Zetasizer, Dr. Curtis Weller for the use of the lyophilizer, Tadas Kasputis, Tim Martin, Sarah Plautz, and Dr. Qiuran Jiang for assistance with cell studies and Dr. Zhongji Han for imaging gels.
- Niidome T, Huang L: Gene therapy progress and prospects: Nonviral vectors. Gene Ther. 2002, 9: 1647-1652. 10.1038/sj.gt.3301923.View ArticleGoogle Scholar
- Donnelly JJ, Ulmer JB, Shiver JW, Liu MA: DNA vaccines. Annu Rev Immunol. 1997, 15: 617-648. 10.1146/annurev.immunol.15.1.617.View ArticleGoogle Scholar
- Pannier AK, Ariazi EA, Bellis AD, Bengali Z, Jordan VC, Shea LD: Bioluminescence imaging for assessment and normalization in transfected cell arrays. Biotechnol Bioeng. 2007, 98: 486-497. 10.1002/bit.21477.View ArticleGoogle Scholar
- Shea LD, Smiley E, Bonadio J, Mooney DJ: DNA delivery from polymer matrices for tissue engineering. Nat Biotechnol. 1999, 17: 551-554. 10.1038/9853.View ArticleGoogle Scholar
- Mintzer MA, Simanek EE: Nonviral vectors for gene delivery. Chem Rev. 2009, 109: 259-302. 10.1021/cr800409e.View ArticleGoogle Scholar
- Li S, Huang L: Nonviral gene therapy: promises and challenges. Gene Ther. 2000, 7: 31-34. 10.1038/sj.gt.3301110.View ArticleGoogle Scholar
- Agarwal A, Mallapragada SK: Synthetic sustained gene delivery systems. Curr Top Med Chem. 2008, 8: 311-330. 10.2174/156802608783790965.View ArticleGoogle Scholar
- Panyam J, Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003, 55: 329-347. 10.1016/S0169-409X(02)00228-4.View ArticleGoogle Scholar
- Bhavsar MD, Amiji MM: Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J Control Release. 2007, 119: 339-348. 10.1016/j.jconrel.2007.03.006.View ArticleGoogle Scholar
- Page DT, Cudmore S: Innovations in oral gene delivery: challenges and potentials. Drug Discov Today. 2001, 6: 92-101. 10.1016/S1359-6446(00)01600-7.View ArticleGoogle Scholar
- Rothman S, Tseng H, Goldfine I: Oral gene therapy: A novel method for the manufacture and delivery of protein drugs. Diabetes Technol Ther. 2005, 7: 549-557. 10.1089/dia.2005.7.549.View ArticleGoogle Scholar
- Jones DH, Corris S, McDonald S, Clegg JC, Farrar GH: Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine. 1997, 15: 814-817. 10.1016/S0264-410X(96)00266-6.View ArticleGoogle Scholar
- Loretz B, Foger F, Werle M, Bernkop-Schnurch A: Oral gene delivery: Strategies to improve stability of pDNA towards intestinal digestion. J Drug Target. 2006, 14: 311-319. 10.1080/10611860600823766.View ArticleGoogle Scholar
- Chen H, Langer R: Oral particulate delivery: status and future trends. Adv Drug Deliv Rev. 1998, 24: 339-350.View ArticleGoogle Scholar
- Roy K, Mao H-Q, Huang S-K, Leong KW: Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999, 5: 387-391. 10.1038/7385.View ArticleGoogle Scholar
- Bowman K, Sarkar R, Raut S, Leong KW: Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. J Control Release. 2008, 132: 252-259. 10.1016/j.jconrel.2008.06.019.View ArticleGoogle Scholar
- Jones DH, Clegg JC, Farrar GH: Oral delivery of micro-encapsulated DNA vaccines. Dev Biol Stand. 1998, 92: 149-155.Google Scholar
- He X-W, Wang F, Jiang L, Li J, Liu S-K, Xiao Z-Y, Jin X-Q, Zhang Y-N, He Y, Li K: Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBsAg. J Gen Virol. 2005, 86: 601-610. 10.1099/vir.0.80575-0.View ArticleGoogle Scholar
- O'Hagan DT, Singh M, Ulmer JB: Microparticles for the delivery of DNA vaccines. Immunol Rev. 2004, 199: 191-200. 10.1111/j.0105-2896.2004.00153.x.View ArticleGoogle Scholar
- Tripathy SK, Svensson EC, Black HB, Goldwasser E, Margalith M, Hobart PM, Leiden JM: Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci USA. 1996, 93: 10876-10880. 10.1073/pnas.93.20.10876.View ArticleGoogle Scholar
- Shyu K-G, Manor O, Magner M, Yancopoulos GD, Isner JM: Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation. 1998, 98: 2081-2087. 10.1161/01.CIR.98.19.2081.View ArticleGoogle Scholar
- Wang J, Zhang P-C, Mao H-Q, Leong KW: Enhanced gene expression in mouse muscle by sustained release of plasmid DNA using PPE-EA as a carrier. Gene Ther. 2002, 9: 1254-1261. 10.1038/sj.gt.3301794.View ArticleGoogle Scholar
- Dang JM, Leong KW: Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev. 2006, 58: 487-499. 10.1016/j.addr.2006.03.001.View ArticleGoogle Scholar
- Malafaya PB, Silva GA, Reis RL: Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv Drug Deliv Rev. 2007, 59: 207-233. 10.1016/j.addr.2007.03.012.View ArticleGoogle Scholar
- Yannas IV: Natural Materials. Biomaterial Science: An Introduction to Materials in Medicine. Edited by: Ratner BD, Hoffman AS, Schoen FJ, Lemons JE. 2004, San Diego: Academic Press, 2Google Scholar
- Czaja WK, Young DJ, Kawecki M, Brown RM: The future prospects of microbial cellulose in biomedical applications. Biomacromolecules. 2007, 8: 1-12. 10.1021/bm060620d.View ArticleGoogle Scholar
- Malafaya PB, Stappers F, Reis RL: Starch-based microspheres produced by emulsion crosslinking with a potential media dependent responsive behavior to be used as drug delivery carriers. J Mater Sci Mater Med. 2006, 17: 371-377. 10.1007/s10856-006-8240-z.View ArticleGoogle Scholar
- Reddy N, Yang Y: Potential of plant proteins for medical applications. Trends Biotechnol. 2011, 29: 490-498. 10.1016/j.tibtech.2011.05.003.View ArticleGoogle Scholar
- Esen A: A proposed nomenclature for the alcohol-soluble proteins (zeins) of maize (Zea mays L.). Journal of Cereal Science. 1987, 5: 117-128. 10.1016/S0733-5210(87)80015-2.View ArticleGoogle Scholar
- Geraghty D, Peifer MA, Rubenstein I, Messing J: The primary structure of a plant storage protein: zein. Nucleic Acids Res. 1981, 9: 5163-5174. 10.1093/nar/9.19.5163.View ArticleGoogle Scholar
- Cabra V, Arregun R, Galvez A, Quirasco M, Vazquez-Duhalt R, Farres A: Characterization of 19 kDa alpha-zein of high purity. J Agric Food Chem. 2005, 53:Google Scholar
- Hurtado-Lopez P, Murdan S: Zein microspheres as drug/antigen carriers: A study of their degradation and erosion, in the presence and absence of enzymes. J Microencapsul. 2006, 23: 303-314. 10.1080/02652040500444149.View ArticleGoogle Scholar
- Pomes AF: Zein. Encyclopedia of Polymer Science and Technology: plastics, resins, rubbers, fibers vol. 15. Edited by: Mark HF, Gaylord NG, Bikales NM. 1971, New York: Interscience Publishers, 125-132.Google Scholar
- Padua GW, Wang Q: Controlled Self-Organization of Zein Nanostructures for Encapsulation of Food Ingredients. Micro/Nanoencapsulation of Active Food Ingredients. Edited by: Huang Q, Given P, Qian M. 2009, Washington D.C.: American Chemical Society, 143-156.View ArticleGoogle Scholar
- Wang Q, Wang JF, Geil PH, Padua GW: Zein adsorption to hydrophilic and hydrophobic surfaces investigated by surface plasmon resonance. Biomacromolecules. 2004, 5: 1356-1361. 10.1021/bm049965r.View ArticleGoogle Scholar
- Deo N, Jockusch S, Turro NJ, Somasundaran P: Surfactant interactions with zein protein. Langmuir. 2003, 19: 5083-5088. 10.1021/la020854s.View ArticleGoogle Scholar
- Parris N, Cooke PH, Hicks KB: Encapsulation of essential oils in zein nanospherical particles. J Agric Food Chem. 2005, 53: 4788-4792. 10.1021/jf040492p.View ArticleGoogle Scholar
- Gong S-J, Sun S-X, Sun Q-S, Wang J-Y, Liu X-M, Liu G-Y: Tablets based on compressed zein microspheres for sustained oral administration: Design, pharmacokinetics and clinical study. J Biomater Appl. 2010, 00: 1-14.Google Scholar
- DiBiase MD, Morrel EM: Oral Delivery of Microencapsulated Proteins. Protein Delivery: Physical Systems. Volume 10. Edited by: Sanders LM, Hendren RW. 1997, New York: Plenum Press, [Borchardt RT (Series Editor): Pharmaceutical Biotechnology]Google Scholar
- Sun Q-S, Dong J, Lin Z-X, Yang B, Wang J-Y: Comparison of cytocompatibility of zein film and other biomaterials and its degradability in vitro. Biopolymers. 2005, 78: 268-274. 10.1002/bip.20298.View ArticleGoogle Scholar
- Fernandez-Carneado J, Kogan MJ, Castel S, Giralt E: Potential peptide carriers: amphipathic proline-rich peptides derived from the N-terminal domain of gamma-zein. Angew Chem Int Ed Engl. 2004, 43: 1811-1814. 10.1002/anie.200352540.View ArticleGoogle Scholar
- Gander B, Blanco-Prieto MJ, Thomasin C, Wandrey C, Hunkeler D: Coacervation and Phase Separation. Encyclopedia of Pharmaceutical Technology, vol. 1. 2006, New York: InformaGoogle Scholar
- Madan PL: Microencapsulation I. Phase separation or coacervation. Drug Dev Ind Pharm. 1978, 4: 95-116. 10.3109/03639047809055641.View ArticleGoogle Scholar
- Arshady R: Microspheres and microcapsules, a survey of manufacturing techniques Part II: Coacervation. Polym Eng Sci. 1990, 30: 905-914. 10.1002/pen.760301505.View ArticleGoogle Scholar
- Hurtado-Lopez P, Murdan S: Formulation and characterisation of zein microspheres as delivery vehicles. J Drug Deliv Sci Tech. 2005, 15: 267-272.View ArticleGoogle Scholar
- Suzuki T, Sato E, Matsuda T, Tada H, Unno K, Kato T: Preparation of zein microspheres conjugated with antitumor drugs available for selective cancer chemotherapy and development of a simple colorimetric determination of drugs in microspheres. Chem Pharm Bull. 1989, 37: 1051-1054. 10.1248/cpb.37.1051.View ArticleGoogle Scholar
- Wang H-J, Lin Z-X, Liu X-M, Sheng S-Y, Wang J-Y: Heparin-loaded zein microsphere film and hemocompatibility. J Control Release. 2005, 105: 120-131. 10.1016/j.jconrel.2005.03.014.View ArticleGoogle Scholar
- Fu J-X, Wang H-J, Zhou Y-Q, Wang J-Y: Antibacterial activity of ciprofloacin-loaded zein microsphere films. Material Science and Engineering C. 2009, 29: 1161-1166. 10.1016/j.msec.2008.09.031.View ArticleGoogle Scholar
- Liu X, Sun Q, Wang H, Zhang L, Wang J: Microspheres of corn protein, zein for an invermectin drug delivery system. Biomaterials. 2005, 26: 109-115. 10.1016/j.biomaterials.2004.02.013.View ArticleGoogle Scholar
- Muthuselvi L, Dhathathreyan A: Simple coacervates of zein to encapsulate gitoxin. Colloids and Surfaces B: Bioinformatics. 2006, 51: 39-43. 10.1016/j.colsurfb.2006.05.012.View ArticleGoogle Scholar
- Zhong Q, Jin M: Zein nanoparticles produced by liquid-liquid dispersion. Food Hydrocolloids. 2009, 23: 2380-2387. 10.1016/j.foodhyd.2009.06.015.View ArticleGoogle Scholar
- Jiang Q, Yang Y: Water-stable electrospun zein fibers for potential drug delivery. J Biomater Sci Polym Ed. 2011, 22: 1393-1408. 10.1163/092050610X508437.View ArticleGoogle Scholar
- Gennadios A, Weller CL: Moisture adsorption by grain protein films. Trans ASAE. 1994, 37: 535-539.View ArticleGoogle Scholar
- Everett DH: Basic Principles of Colloid Science. London: Royal Society of Chemistry; 1988.View ArticleGoogle Scholar
- O'Hagan DT: The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat. 1996, 189: 477-482.Google Scholar
- Clark MA, Jepson MA, Hirst BH: Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev. 2001, 50: 81-106. 10.1016/S0169-409X(01)00149-1.View ArticleGoogle Scholar
- Hombach J, Bernkop-Schnurch A: Handbook of experimental pharmacology. Handb Exp Pharmacol. 2010, 197: 251-266. 10.1007/978-3-642-00477-3_9.View ArticleGoogle Scholar
- Astete CE, Sabliov CM: Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed. 2006, 17: 247-289. 10.1163/156856206775997322.View ArticleGoogle Scholar
- Mao H-Q, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong KW: Chitosan-DNA nanoparticles as gene carriers: synthesis characterization and transfection efficiency. J Control Release. 2001, 70: 399-421. 10.1016/S0168-3659(00)00361-8.View ArticleGoogle Scholar
- Masotti A, Bordi F, Ortaggi G, Marino F, Palocci C: A novel method to obtain chitosan/DNA nanospheres and a study of their release properties. Nanotechnology. 2008, 19: 055302-10.1088/0957-4484/19/05/055302.View ArticleGoogle Scholar
- Jang J-H, Shea LD: Controllable delivery of non-viral DNA from porous scaffolds. J Control Release. 2003, 86: 157-168. 10.1016/S0168-3659(02)00369-3.View ArticleGoogle Scholar
- Luo Y, Zhang B, Whent M, Yu L, Wang Q: Preparation and characterization of zein/chitosan complex for encapsulation of α-tocopherol, and its in vitro controlled release study. Colloids Surf B Biointerfaces. 2011, 85: 145-152. 10.1016/j.colsurfb.2011.02.020.View ArticleGoogle Scholar
- Podaralla S, Perumal O: Preparation of Zein Nanoparticles by pH Controlled Nanoprecipitation. J Biomed Nanotechnol. 2010, 6: 312-317. 10.1166/jbn.2010.1137.View ArticleGoogle Scholar
- Lawton JW: Zein: A History of Processing and Use. Cereal Chemistry. 2002, 79: 1-18. 10.1094/CCHEM.2002.79.1.1.View ArticleGoogle Scholar
- Gong S, Wang H, Sun Q-S, Xue S-T, Wang J-Y: Mechanical properties and in vitro biocompatibility of porous zein scaffolds. Biomaterials. 2006, 27: 3793-3799. 10.1016/j.biomaterials.2006.02.019.View ArticleGoogle Scholar
- Mathiowitz E, Bernstein H, Morrel E, Schwaller K: Method for producing protein microspheres. Patent US ed., vol. 5,271,961; 1993
- Gan Q, Wang T, Cochrane C, McCarron P: Modulation of surface charge, particle size and morphological properties of chitosan–TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces. 2005, 44: 65-73. 10.1016/j.colsurfb.2005.06.001.View ArticleGoogle Scholar
- Demetriades K, Coupland JN, McClements DJ: Physical Properties of Whey Protein Stabilized Emulsions as Related to pH and NaCl. J Food Sci. 1997, 62: 342-347. 10.1111/j.1365-2621.1997.tb03997.x.View ArticleGoogle Scholar
- Lai LF, Guo HX: Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting. Int J Pharm. 2011, 404: 317-323. 10.1016/j.ijpharm.2010.11.025.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.